BioNTech
BNTX | NASDAQ
$85.26
-$0.34 (-0.40%)
At close: Nov 16, 2026, 4:00 PM ET
$86.45
+$1.19 (+1.40%)
After-hours:
Nov 16, 2026, 7:44 PM ET
BioNTech Company Profile
Company profile explainedCompany Profile
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Key Executives
| Name | Position |
|---|---|
| Ugur Sahin | Co-Founder, Chief Executive Officer & Chair of the Management Board |
| Kylie Jimenez | Chief People Officer & Member of Management Board |
| Ramon Zapata-Gomez | Chief Financial Officer & Member of Management Board |
| Sierk Pötting | MD, Chief Operating Officer & Member of Management Board |
| Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board |
| Douglas Maffei | Vice President of Strategy & Investor Relations |
| James Timothy Patrick Ryan | Chief Legal & Business Officer and Member of the Management Board |
| Jasmina Alatovic | Vice President Corporate Communications |
| Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting |
| Ozlem Tureci | Co-Founder, Chief Medical Officer & Member of Management Board |
BioNTech
| Country | Germany |
| IPO Date | Oct 10, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7,807 |
| CEO | Ugur Sahin |
Contact Details
An der Goldgrube 12 Mainz,
RP 55131 Germany
Stock Details
| Ticker Symbol | BNTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001776985 |
| CUSIP Number | 09075V102 |
| ISIN Number | US09075V1026 |
| SIC Code | 2836 |
Recent News
- 4 days ago / barrons.comBioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.
- 5 days ago / fool.comBioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
- 8 days ago / fool.comBioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
- 11 days ago / 247wallst.comModerna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
- 11 days ago / fool.comAxsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
- 13 days ago / seekingalpha.comBioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
- 13 days ago / seekingalpha.comBioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comBioNTech Q3 Earnings Call Highlights
- 14 days ago / globenewswire.comBioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
- 20 days ago / 247wallst.comModerna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Add to Watchlist
Select watchlists to add or remove BNTX